<DOC>
	<DOCNO>NCT02913924</DOCNO>
	<brief_summary>The protocol double-blind , placebo-controlled inpatient outpatient study , combine inpatient model cannabis withdrawal clinical treatment cannabis use disorder use clonazepam versus placebo . 80 patient seek treatment cannabis use disorder enrol inpatient phase 5 night . After discharge inpatient phase , 12-weeks outpatient treatment conduct . This combined design provide comprehensive understanding clonazepam 's effect individual cannabis use disorder across range outcome measure also test medication 's ability prevent relapse cannabis-abstinent patient .</brief_summary>
	<brief_title>Effect Clonazepam Cannabis Withdrawal Relapse Treatment-seeking Patients</brief_title>
	<detailed_description>Patients seek treatment Cannabis Use Disorder ( CUD ) enrol inpatient laboratory 5 night , initiate medication assess influence clonazepam ( placebo ) ( 1 ) cannabis withdrawal ( mood , sleep , cannabis craving , food intake ) , rating associate medication abuse liability , cognitive performance , ( 2 ) relapse cannabis use patient ( abstinent cannabis ) leave inpatient setting maintain clonazepam ( placebo ) 8 week ( 4-week , medication-free follow ) . This combined design provide comprehensive understanding clonazepam 's effect individual cannabis use disorder across range outcome measure ( safety , abuse liability , withdrawal symptom ) also test medication 's ability prevent relapse cannabis-abstinent patient .</detailed_description>
	<mesh_term>Marijuana Abuse</mesh_term>
	<mesh_term>Clonazepam</mesh_term>
	<criteria>Meets DSM 5 criterion CUD least moderate severity ( â‰¥ 4 symptom ) seek treatment cannabis use . Reports use cannabis minimum 5 day per week past 4 week 1865 year age Individuals lifetime DSM5 diagnosis schizophrenia , schizoaffective disorder , bipolar disorder Individuals meet current DSM5 criterion psychiatric disorder may , accord investigator 's judgment , require either pharmacological nonpharmacological intervention course study Participants take psychotropic medication Known history allergy , intolerance hypersensitivity benzodiazepine Episodic chronic use benzodiazepine Pregnancy , lactation , failure use adequate contraceptive method ( condom , diaphragm , birth control pill , IUD ) female patient currently engage sexual activity men . Unstable medical condition , poorly control hypertension , might make participation hazardous Participants current DSM5 diagnosis alcohol substance use disorder ( abuse dependence ) cannabis nicotine use disorder Are legally mandate participate substance use disorder treatment program Increased risk suicide Current parole probation Recent history significant violent behavior History current past diagnosis glaucoma History benzodiazepine sedative hypnotic use disorder</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Marijuana</keyword>
	<keyword>Treatment</keyword>
</DOC>